Bcl-xL antagonist 2

• CAT Number: I045493
• CAS Number: 1235032-75-3
• Molecular Formula: C21H16N4O3S2
• Molecular Weight: 436.51
• Purity: ≥95%
• Synonyms: 2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1H-isoquinolin-2-yl]-1,3-thiazole-4-carboxylic acid
• InChI: InChI=1S/C21H16N4O3S2/c26-18(24-20-22-15-6-1-2-7-17(15)30-20)13-5-3-4-12-8-9-25(10-14(12)13)21-23-16(11-29-21)19(27)28/h1-7,11H,8-10H2,(H,27,28)(H,22,24,26)
• InChIKey: PHCCZZHEZZPUGG-UHFFFAOYSA-N
• SMILES: C1CN(CC2=C1C=CC=C2C(=O)NC3=NC4=CC=CC=C4S3)C5=NC(=CS5)C(=O)O

Bcl-xL antagonist 2 (Cat No.: I045493) is a small-molecule inhibitor that selectively targets B-cell lymphoma-extra large (Bcl-xL), an anti-apoptotic protein in the Bcl-2 family that regulates mitochondrial outer membrane permeabilization. By binding to Bcl-xL’s hydrophobic groove, it disrupts interactions with pro-apoptotic proteins such as Bax and Bak, promoting apoptosis in cancer cells dependent on Bcl-xL for survival. This compound is used in oncology research to study apoptosis regulation, overcome resistance to chemotherapy, and explore targeted cancer therapies that exploit vulnerabilities in tumor cell survival pathways.

Reference

[1]. Koehler MF, et al. Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. ACS Med Chem Lett. 2014;5(6):662-667.
[Content Brief]

[2]. Wang L, et al. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor. ACS Med Chem Lett. 2020;11(10):1829-1836.
[Content Brief]